OR WAIT null SECS
October 17, 2017
CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site
October 16, 2017
Piramal is investing $55 million into the expansion of its API manufacturing capabilities and capacities across sites in North America and Asia.
October 14, 2017
Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.
October 13, 2017
Predicted areas of growth include flow chemistry, fermentation, repatriation of overseas funds, oncology, and API/product integration, but the rate of change is unclear.
October 12, 2017
Investments include the installation of development and analytical equipment to support the development of highly potent APIs as well as a new 2800-liter hydrogenator and 1500-mm diameter centrifuge for increased flexibility and capacity within the manufacturing plant.
October 11, 2017
CordenPharma will integrate the Hospira Boulder API manufacturing facility into the CordenPharma Colorado network for highly potent and oncology APIs.
October 02, 2017
CDMOs have established strategies for handling new chemical entities with unknown biological activity.
Mergers and acquisitions are positive for the CDMO industry, but there is a downside.
September 26, 2017
Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.
September 21, 2017
Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.